UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Annual Report for the financial year 2025/2026 for Biovica international AB is published today on our website.Please see link below.ContactTheis Kipling, CEOTelefon: +46 (0) 76 666 36 52E-post: theis.kipling@biovica.comAnders Morén, CFOPhone: +46 73 125 92 46E-mail: anders.moren@biovica.comBiovica - Treatment decisions with greater confidenceBiovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.comAttachmentsBiovica 25 26 ENG FinalSOURCE: Biovica InternationalView the original press release on ACCESS Newswire
Biovica International AB - Annual Report for The Financial Year 2025/2026 Published
UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Annual Report for the financial year 2025/2026 for Biovica international AB is published today on our website.Please see link below.ContactTheis Kipling, CEOTelefon: +46 (0) 76 666 36 52E-post: theis.kipling@biovica.comAnders Morén, CFOPhone: +46 73 125 92 46E-mail: anders.moren@biovica.comBiovica - Treatment decisions with greater confidenceBiovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.comAttachmentsBiovica 25 26 ENG FinalSOURCE: Biovica InternationalView the original press release on ACCESS Newswire
